Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: selection of the scaffold

…, N Choi, W Issa, K Macfarlane, N Thienthong…

文献索引：Jones, Eric D.; Vandegraaff, Nick; Le, Giang; Choi, Neil; Issa, William; MacFarlane, Katherine; Thienthong, Neeranat; Winfield, Lisa J.; Coates, Jonathan A.V.; Lu, Long; Li, Xinming; Feng, Xiao; Yu, Changjiang; Rhodes, David I.; Deadman, John J. Bioorganic and Medicinal Chemistry Letters, 2010 , vol. 20, # 19 p. 5913 - 5917

全文：HTML全文

被引用次数: 27

摘要

The Human Immunodeficiency Virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS), a disease for which there is presently no cure. Therapy currently consists of a combination of three drugs targeting two or more critical targets within the viral life cycle in what has proved to be an extremely successful treatment regimen known as highly active antiretroviral therapy (HAART). Raltegravir (Isentress™), 1 a drug approved by the FDA in October ...